Erasca to Engage with Investors at Notable Conferences
Erasca, Inc. (NASDAQ: ERAS), a company at the forefront of precision oncology, is excited to announce its participation in prominent investor conferences set for June. The team's focus is on developing effective therapies specifically for patients facing cancers driven by RAS/MAPK pathways, an endeavor that reflects their commitment to innovation in cancer treatment.
Upcoming Conferences for Erasca
The first significant event is the Jefferies Global Healthcare Conference, running from June 3 to June 5. Erasca will partake in a fireside chat on June 4 at 5:30 PM Eastern Time, providing a platform to discuss its ongoing projects and future plans.
Details of the Jefferies Conference
This conference is an excellent opportunity for stakeholders to gain insights into Erasca's journey. The interactive format allows attendees to engage with leadership, fostering a deeper understanding of their strategic approach to combating cancer and navigating the complex landscape of oncology research.
Goldman Sachs Global Healthcare Conference
Shortly after, Erasca will also be present at the Goldman Sachs 46th Annual Global Healthcare Conference from June 9 to June 11. The company will host another fireside chat on June 10 at 2:40 PM Eastern Time, ensuring that investors gather crucial information about their developments.
Engagement and Insights
The Goldman Sachs conference provides yet another avenue for Erasca to connect directly with its investor community, illustrating their transparency and commitment to open dialogue regarding their therapeutic strategies.
Online Access to Conference Events
Erasca will provide live audio webcasts for both conferences on their official site, ensuring that those who cannot attend in person can still be part of the discussion. An archived version will also be available for 30 days after the events, allowing wider accessibility for information dissemination.
About Erasca and Its Mission
Erasca's aspiration is encapsulated in its name: to erase cancer. The company is dedicated to discovering and commercializing therapies that specifically target cancers arising from the RAS/MAPK pathways. Co-founded by leading figures in precision oncology, the company aims to develop innovative treatments that not only target cancerous cells but also provide a comprehensive approach to disruption of the pathway fueling these malignancies.
Expert Guidance
Supported by a distinguished scientific advisory board comprising some of the foremost authorities in oncology, Erasca's ambition is guided by insights from top expertise in the field. Their research is not just about targeting cancer but innovating methods that could revolutionize patient outcomes.
Contact Information
Individuals seeking further details regarding Erasca’s initiatives may reach out to Joyce Allaire of LifeSci Advisors, LLC via email at jallaire@lifesciadvisors.com. Erasca welcomes all inquiries and feedback as they strive to further their mission.
Frequently Asked Questions
What is Erasca's primary focus?
Erasca focuses on developing therapies for patients with cancers driven by the RAS/MAPK pathways.
When will Erasca present at the Jefferies Global Healthcare Conference?
Erasca's presentation will be on June 4 at 5:30 PM Eastern Time.
How can I access the conference webcasts?
Live and archived webcasts will be available on Erasca's official website.
What kind of therapies is Erasca developing?
Erasca is creating innovative therapies aimed at comprehensively targeting RAS/MAPK pathways.
Who can I contact for more information about Erasca?
You can contact Joyce Allaire at LifeSci Advisors via email at jallaire@lifesciadvisors.com.